PLA2G7 and coronary artery disorder: And Darapladibas, a selective reversible inhibitor of Lp-PLA2, could inhibit plasma Lp-PLA2 activity and reduce the levels of inflammatory biomarkers, such as IL-6 and hsCRP, in patients with CHD or its risk-equivalent diseases receiving intensive atorvastatin therapy [11].